Lamotrigine Dosing for Absence Seizures

Initial Dosing Protocol

The American Academy of Neurology recommends starting lamotrigine at 25 mg once daily for 14 days, then increasing to 50 mg once daily for the next 14 days, with subsequent gradual titration based on clinical response, to minimize the risk of serious rash in patients with absence seizures 1
Slow titration is mandatory to prevent serious cutaneous reactions, including Stevens-Johnson syndrome, with a recommended initial dosage and 2-week intervals between dose increases, in patients taking lamotrigine for absence seizures 1, 2
Exceeding the recommended initial dosage is a major risk factor for severe rash in patients with absence seizures 1

The American Academy of Neurology recommends reducing lamotrigine doses by approximately 50% when co-administered with valproic acid, due to a dramatic increase in half-life to 48-59 hours, in patients with absence seizures 1
Enzyme-inducing antiepileptics, such as phenytoin, carbamazepine, barbiturates, topiramate, and oxcarbazepine, require higher lamotrigine doses due to increased metabolism, in patients with absence seizures 2, 3
Combined hormonal contraceptives may reduce lamotrigine effectiveness, requiring dose adjustments or alternative contraception, in patients with absence seizures 2, 3

A single loading dose of 6.5 mg/kg orally can be given only if the patient was on lamotrigine for more than 6 months, has no history of rash, and has been off medication for less than 5 days, in an emergency department setting, for patients with absence seizures 2, 4

Baseline complete blood count, liver function tests, and renal function tests should be obtained before starting lamotrigine, though no routine monitoring is required during maintenance therapy, in patients with absence seizures 1
Lamotrigine levels should be checked when patients start combined hormonal contraceptives, to ensure adequate dosing, in patients with absence seizures 1
Patients should be monitored for rash, particularly during the first 8 weeks of therapy, to minimize the risk of serious cutaneous reactions, in patients with absence seizures 1